新型前鼻拭子检测 SARS-CoV-2 的评估。
Evaluation of a novel anterior nasal swab for the detection of SARS-CoV-2.
机构信息
Department of Microbiology, St Vincent's Pathology, St Vincent's Hospital Melbourne, Australia; Department of Medicine, St Vincent's Hospital at the University of Melbourne, Australia.
Department of Medicine, St Vincent's Hospital at the University of Melbourne, Australia; Department of Pharmacy, St Vincent's Hospital Melbourne, Australia.
出版信息
J Virol Methods. 2023 Jun;316:114713. doi: 10.1016/j.jviromet.2023.114713. Epub 2023 Mar 18.
BACKGROUND
During the course of the COVID-19 pandemic, nasopharyngeal swabs, combined throat and nose swabs and saliva samples have been evaluated for SARS-CoV-2 detection using nucleic acid amplification tests (NAT). Literature on anterior nasal swabs is limited. We investigated a novel anterior nasal swab that has been designed to standardised self-collection, maximise sample uptake and improve user comfort. We used combined throat and nose swabs and neat saliva samples as the comparators.
RESULTS
The overall positive percentage agreement between the Rhinoswab™ and the combined throat and nose swab was 95.2 % at day 2 post participant recruitment and 93.3 % on day 4 post participant recruitment. This was favourable to the positive percentage agreement with saliva at the same time points.
CONCLUSION
In our study the Rhinoswab™ performed equally well in comparison to a combined throat and nose swab for the laboratory detection of SARS-CoV-2 using nucleic acid amplification techniques.
背景
在 COVID-19 大流行期间，已经使用核酸扩增检测（NAT）评估了鼻咽拭子、咽鼻联合拭子和唾液样本用于 SARS-CoV-2 检测。有关前鼻拭子的文献有限。我们研究了一种新型的前鼻拭子，旨在标准化自我采集，最大限度地提高样本采集量并提高用户舒适度。我们使用咽鼻联合拭子和纯唾液样本作为对照。
结果
Rhinoswab™与咽鼻联合拭子在招募后第 2 天的总阳性百分比一致性为 95.2%，招募后第 4 天的阳性百分比一致性为 93.3%。这与同一时间点的唾液阳性百分比一致。
结论
在我们的研究中，Rhinoswab™与咽鼻联合拭子相比，使用核酸扩增技术检测 SARS-CoV-2 的实验室检测结果相当。
Zotero 插件